Eli Lilly and Company’s Stock Price Drops to $725.72, Suffers 4.21% Decline – A Critical Market Update

Eli Lilly and Company (LLY)

725.72 USD -31.88 (-4.21%) Volume: 5.46M

Eli Lilly and Company’s stock price stands at 725.72 USD, witnessing a downturn of -4.21% this trading session with a trading volume of 5.46M. The pharmaceutical giant’s stock performance has dipped -1.87% Year-to-Date (YTD), indicating a slow start to the year.

Latest developments on Eli Lilly and Company

Recently, the FDA approved Eli Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, marking a significant expansion in the drug’s usage to the second major type of inflammatory bowel disease. While the company is considering offering more Zepbound doses in vials at a lower cost, there have been concerns about whether Eli Lilly’s stock has peaked. The stock price has seen fluctuations, with a fall after the 2024 guidance missed forecasts. Despite this, Eli Lilly made headlines with a new manufacturing collaboration effort with Purdue and Merck. With ongoing developments and market reactions, investors are closely watching Eli Lilly’s stock movements.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Eli Lilly & Company seems to have a promising long-term outlook. With a Growth score of 4 and a Momentum score of 4, the company appears to be on a positive trajectory for future expansion and performance. Additionally, the Dividend score of 3 suggests that investors may also benefit from potential returns in the form of dividends. However, the Value and Resilience scores of 2 indicate that there may be some challenges in terms of the company’s valuation and ability to withstand market fluctuations.

Eli Lilly & Company, a pharmaceutical giant that operates globally, is known for its wide range of products in various therapeutic areas such as neuroscience, endocrine, oncology, and animal health. With a focus on innovation and research, the company has been able to maintain a strong growth momentum, as reflected in its high Growth and Momentum scores. While there may be some room for improvement in terms of value and resilience, Eli Lilly & Company’s overall outlook appears to be optimistic based on the Smartkarma Smart Scores.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma